Can Microneedle Patches Deliver Peptide Drugs? What Human Trials Show
Peptide microneedle patches have reached human testing, but results depend on the drug and device. An abaloparatide patch delivered drug in a small study, then failed to show noninferiority to injection for spine bone-density gains in a larger trial.
Can a patch with microscopic projections deliver a peptide drug through the skin? For one formulation of abaloparatide, human studies show drug absorption and changes in bone markers. A larger trial also found a limit: the patch did not meet its prespecified test for noninferiority to subcutaneous injection on the main bone-density outcome. Those findings describe a particular drug and solid microstructured transdermal system (sMTS), not every microneedle patch or peptide. Miller et al., 2021; Lewiecki et al., 2023
What kind of patch was tested in people?
The abaloparatide-sMTS has drug-coated microstructures that deliver the peptide into the skin. It is different from a dissolving microneedle formulation, in which the needle material dissolves and releases its payload. It is also different from an ordinary, needle-free transdermal patch and from a subcutaneous injection. In a single-arm Phase 1b study, 22 trained postmenopausal women with low bone mineral density used the sMTS under study conditions. Investigators measured systemic drug exposure and a bone-formation marker; they reported consistent exposure over the study and increases in that marker. The study had no randomized injection comparison for clinical efficacy. Its common adverse events included application-site redness, pain and swelling, so “painless” is not a finding supported by this trial. Miller et al., 2021
What happened in the larger trial?
A randomized, open-label Phase 3 trial assigned 511 postmenopausal women with osteoporosis to abaloparatide-sMTS or subcutaneous abaloparatide for 12 months. The primary endpoint was the percentage change in lumbar-spine bone mineral density. It increased by 7.14% with sMTS and 10.86% with injection; the reported treatment difference was −3.72 percentage points (95% CI −5.01 to −2.43). The patch did not demonstrate noninferiority under the study’s prespecified margin. Administration-site reactions were reported in 94.4% of the sMTS group and 70.5% of the injection group. Few new clinical fractures occurred, so this trial does not establish a comparative fracture benefit for the patch. Lewiecki et al., 2023
Do those results apply to GLP-1 drugs or dissolving patches?
No direct clinical inference follows for semaglutide, tirzepatide or a different patch design. A separate laboratory and animal study tested a dissolving microneedle formulation carrying exenatide. It reported 89.71% relative bioavailability for its own formulation in preclinical pharmacokinetic testing and glucose effects in diabetic mice. That is not an 80–90% bioavailability result for peptide patches generally, nor a human result for the drugs linked on this page. The study does not establish a universal dissolution time, room-temperature shelf life, patient preference or adherence benefit. Xu et al., 2025
Is the studied abaloparatide patch an approved product?
The current U.S. TYMLOS prescribing information describes abaloparatide injection for subcutaneous use. It does not make the investigational sMTS an approved route. Evidence for one product or device cannot substitute for testing another peptide, formulation, route and intended use. The earlier claim on this page about an unnamed roughly 60-person Phase 1 peptide-patch trial, with results due in 2026, could not be tied to a verifiable primary record and has been removed.
Evidence level: low for a general peptide-patch claim. The Phase 3 abaloparatide result is human evidence for that specific product and bone-density endpoint; the exenatide dissolving-patch result is preclinical. This article is educational, not medical advice or a recommendation to use a product or change a prescribed route.
Sources & Citations
- 4
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.